Business context and reporting period
The supplied filing is Athira Pharma, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2022—not a filing identified as Leonabio, Inc. This summary therefore covers Athira Pharma (Nasdaq: ATHA). Athira is a clinical-stage biopharmaceutical company developing small molecules for neurological disorders; it has no approved products and has generated no product revenue.
Key financial metrics
| Metric | Q1 2022 | Q1 2021 or comparison |
|---|---|---|
| Product revenue | None | None |
| Grant income | $2.2 million | $1.8 million |
| Research and development expense | $14.5 million | $7.4 million; up 94% |
| General and administrative expense | $8.9 million | $3.3 million; up 168% |
| Total operating expenses | $23.4 million | $10.8 million; up 117% |
| Net loss | $21.0 million | $8.9 million |
| Net loss per share | $0.56 | $0.25 |
| Cash used in operating activities | $16.6 million | $7.3 million |
Gross profit and operating margins are not meaningful because the company has no product sales. Cash, cash equivalents and investments totaled $301.2 million at March 31, 2022, including $117.8 million of cash and cash equivalents. Total liabilities were $11.0 million, primarily operating lease liabilities; the filing reports no borrowing debt. Operating lease obligations were $2.6 million undiscounted, including $0.4 million due within 12 months.
Material changes versus the prior comparable period
Net loss increased by $12.1 million year over year as operating expenses rose substantially. R&D spending on fosgonimeton increased by $4.0 million, mainly for clinical-trial enrollment and site activity; personnel and stock-based compensation also increased. G&A rose by $5.6 million, reflecting higher personnel costs, legal expenses, professional services and business development. Operating cash use more than doubled. Unlike Q1 2021, when a follow-on offering provided $97.2 million of net financing cash, Q1 2022 financing cash was limited to $0.2 million from stock-option exercises.
Outlook, commentary, risks and unusual items
- Management estimated that the $301.2 million of cash, cash equivalents and investments at quarter-end would fund operating expenses and capital needs for at least 12 months following the May 12, 2022 filing date. The company expects losses and spending to increase as trials and development programs advance, and says it will need substantial additional funding.
- Fosgonimeton’s ACT-AD Phase 2 topline results were expected by the end of Q2 2022; LIFT-AD Phase 2/3 topline results were expected in the first half of 2023. In January 2022, the planned LIFT-AD sample size was increased from 300 to approximately 420. In May 2022, Athira announced an additional 12-month extension to its open-label extension studies, potentially allowing up to 18 months of open-label treatment.
- The NIH grant may provide up to $15.2 million in total. Athira had recognized $12.1 million cumulatively by March 31, 2022 and expected to recognize the remaining $3.1 million during 2022, subject to qualifying expenses.
- A board special committee found that former CEO Leen Kawas altered images in her dissertation and at least four co-authored papers. It also found that Athira cited challenged papers in certain communications and applications and that the WSU dihexa patent licensed to Athira incorporated some altered images. WSU’s separate review was ongoing; the filing says its outcome and timing were uncertain. The matter creates potential scientific-credibility, intellectual-property, regulatory, funding and reputational risks.
- Consolidated securities class actions and two shareholder derivative suits concern alleged omissions or misstatements related to the research-image allegations. The company said outcomes and possible losses could not be reasonably estimated and no liability was recorded as of March 31, 2022. A stockholder proxy contest was also underway, adding potential distraction and costs.
- Management cited clinical-development uncertainty, potential enrollment delays, reliance on third-party research and manufacturing providers, competition, regulatory and reimbursement uncertainty, and possible COVID-19 impacts. Early clinical data included only 11 patients with mild-to-moderate Alzheimer’s disease; the company cautioned that early results may not predict later trial outcomes.
- Disclosure controls and procedures were assessed as effective at the reasonable-assurance level; no material change in internal control over financial reporting was reported for the quarter.
Most important facts for investors to verify
- Confirm the issuer identity: the provided filing is for Athira Pharma, Inc. (ATHA), not Leonabio, Inc.
- Check ACT-AD and LIFT-AD results, endpoint outcomes, trial timelines and the consequences of the increased LIFT-AD enrollment target.
- Track the WSU investigation, the status and potential implications for Athira’s licensed dihexa intellectual property, and developments in the securities and derivative litigation.
- Assess cash burn against management’s runway estimate, anticipated trial and legal spending, and the timing and terms of any future financing.
- Verify the remaining NIH grant recognition and cash collection, and consider potential dilution from future equity issuance and outstanding equity awards.